Úskalí léčby chronické myeloidní leukemie dasatinibem - plicní arteriální hypertenze jako vzácná komplikace

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Pitfalls of treating chronic myeloid leukaemia with dasatinib - pulmonary arterial hypertension as a rare complication
Authors

ČIČÁTKOVÁ Petra KVETKOVÁ Anežka HORŇÁK Tomáš SEMERÁD Lukáš ŽÁČKOVÁ Daniela

Year of publication 2021
Type Article in Periodical
Magazine / Source Transfuze a hematologie dnes
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.prolekare.cz/casopisy/transfuze-hematologie-dnes/2021-2-21/uskali-lecby-chronicke-myeloidni-leukemie-dasatinibem-plicni-arterialni-hypertenze-jako-vzacna-komplikace-127610
Doi http://dx.doi.org/10.48095/cctahd2021166
Keywords chronic myeloid leukaemia; dasatinib; pleural effusions; pulmonary arterial hypertension
Description Dasatinib is a potent tyrosine kinase inhibitor of not only Bcr-Abl1, but also of the Src kinase family, c-kit and PDGFR-b. This “offtarget” effect is the probable cause of pleural effusions, which complicate dasatinib therapy in about one third of patients. The following case report describes a chronic myeloid leukaemia patient with not only recurrent pleural effusions but also pulmonary arterial hypertension as a serious adverse event leading to dasatinib discontinuation.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info